A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty

Domínguez‐Rodríguez, Alberto; Abreu-González, Pedro; García-González, Martín J.; Kaski, Juan Carlos; Reíter, Russel J.; Jiménez-Sosa, Alejandro

doi:10.1016/j.cct.2006.10.007

Cited by 62 publications

(60 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melatonin has well documented protective effects against the symptoms of severe sepsis/shock in humans; its use for this condition significantly improves survival [24,30]. In addition, it has been shown that M can confer cardioprotection in patients with acute myocardial ischemia [51]. Moreover, studies of prolonged NOS inhibition in patients with septic shock showed hemodynamic toxicity and excess mortality at higher doses [52].…”

Section: Discussionmentioning

confidence: 98%

Melatonin and 1400 W Ameliorate both Intestinal and Remote Organ Injury Following Mesenteric Ischemia/Reperfusion

Kesik

Güven

Vurucu

et al. 2009

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Melatonin and 1400 W Ameliorate both Intestinal and Remote Organ Injury Following Mesenteric Ischemia/Reperfusion

Kesik

Güven

Vurucu

et al. 2009

Journal of Surgical Research

View full text Add to dashboard Cite

“…The available scientific evidence has led our group to carry out a phase II clinical trial (NCT00640094) to demonstrate inhibition of reperfusion damage by administering melatonin to patients with acute myocardial infarction immediately before primary percutaneous coronary intervention [11]. Melatonin is an endogenous molecule with few side effects and a low monetary cost.…”

Section: To the Editormentioning

confidence: 99%

Melatonin: Still a forgotten antioxidant

Abreu-González

2011

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

“…1 In this population, the frequency of primary and chronic secondary headaches, especially migraine, was higher than in the general Japanese population.Administration of interferon beta was related to a higher frequency of primary and chronic secondary headaches, especially migraine without aura. A small magnetic resonance imaging (MRI) study showed increased iron depositions in the periaqueductal grey matter in migraineurs, suggestive of a disturbed central antinociceptive neuronal network.…”

mentioning

confidence: 96%

Abstracts and Citations

Kaniecki¹,

Taylor²,

Stillman³

2009

Headache

View full text Add to dashboard Cite

A, Lines CR, Winner P, Shapiro RE. Age effects on placebo response rates in clinical trials of acute agents for migraine: Pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009;29:711-718.This study examined the effect of age on placebo response rates in rizatriptan trials in adults. Data from 8 rizatriptan adult trials involving patients treating moderate/severe migraine attacks with rizatriptan 5 mg (N = 1819), rizatriptan 10 mg (N = 2046), or placebo (N = 1322) were pooled for post hoc analysis. Logistic regression was used to model 2-hour pain relief (reduction to mild or none) and 2-hour pain freedom rates by treatment groups. Older patients had lower placebo response rates than younger patients; the estimated odds ratio (older vs younger) for a 10-year age increase was 0.83 for pain relief (95% confidence interval [CI] 0.75, 0.93) and 0.81 for pain freedom (95% CI 0.68, 0.97). The response proportion vs age trend was flat for rizatriptan 5 mg and slightly increased for rizatriptan 10 mg. The treatment-byage interaction was significant for pain relief (P < .001) and pain freedom (P = .001), suggesting an increasing trend of treatment advantage of rizatriptan over placebo as age increased. Age appeared to be an important predictor of placebo response rate in rizatriptan trials, with older patients being less likely to respond to placebo and more likely to respond to rizatriptan.Comments: Although the efficacy of 5-HT1B/1D receptor agonists (triptans) for the acute treatment of migraine attacks in adults is well established, the response to triptans in patients <18 years old is less clear. Many of the initial trials of triptans in children and adolescents failed to demonstrate an advantage over placebo.Various explanations have been proposed, including the relatively short duration of migraine attacks, delays in accessing treatment, study design issues, and pharmacokinetic or pharmacodynamic differences. A common observation in adolescent/pediatric migraine studies has been that whereas drug response rates tend to be similar to those seen in adults, placebo response rates tend to be higher, thereby leading to a lack of separation between drug and placebo. Within the adolescent/pediatric group an inverse relationship between placebo response rate and age has been demonstrated. 1,2 In triptan trials in adults, formulation has been demonstrated to impact placebo response, but it is currently not clear whether an age-related effect on placebo response rates exists. 3 To investigate this issue, Tony Ho et al performed a post hoc analysis of placebo data from pooled phase III adult clinical trials (>5000 patients) with rizatriptan. The results suggest that age was an important predictor of placebo response, with younger adult patients being more likely to respond to placebo. The authors proposed the high placebo response rate observed in adolescents and children represents one end of a continuum which extends into adulthood. A second analysis of drug response vs age documented an effect of age on drug re...

show abstract

A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty

Cited by 62 publications

References 48 publications

Melatonin and 1400 W Ameliorate both Intestinal and Remote Organ Injury Following Mesenteric Ischemia/Reperfusion

Melatonin and 1400 W Ameliorate both Intestinal and Remote Organ Injury Following Mesenteric Ischemia/Reperfusion

Melatonin: Still a forgotten antioxidant

Abstracts and Citations

Contact Info

Product

Resources

About